Neurosurgery department, Reims University Hospital, Reims, France.
Neurosurgery department, Reims University Hospital, Reims, France.
Orthop Traumatol Surg Res. 2016 Apr;102(2):255-6. doi: 10.1016/j.otsr.2015.11.013. Epub 2016 Mar 3.
Recombinant human bone morphogenetic protein-2 (rhBMP-2) was recently licensed for local administration during posterior lumbar fusion. In this indication, considerable uncertainty remains about the nature and mechanisms of the many adverse effects of rhBMP-2, such as ectopic bone formation. We report a case of ectopic bone formation with impingement on a facet joint and incapacitating low back pain after minimally invasive transforaminal L5-S1 interbody fusion with local application of rhBMP-2 (InductOs(®)). Revision surgery was eventually performed to alleviate the symptoms by removing the ectopic bone. Caution is in order regarding the use of rhBMP-2 during posterior lumbar fusion. Every effort should be made to minimise the risk of complications.
重组人骨形态发生蛋白-2（rhBMP-2）最近被批准用于后路腰椎融合术中的局部给药。在这种适应证下，rhBMP-2 引起的许多不良反应（如异位骨形成）的性质和机制仍存在很大的不确定性。我们报告了一例因微创经椎间孔 L5-S1 椎体间融合术局部应用 rhBMP-2（InductOs(®)）而导致的异位骨形成、关节突关节撞击和严重的下腰痛病例。最终通过手术切除异位骨来缓解症状。在后路腰椎融合术中使用 rhBMP-2 时应谨慎。应尽一切努力将并发症的风险降至最低。
